Bangladeshi children to receive two new vaccines
These introductions will benefit more than 3 million children. PCV defends children against pneumococcal pneumonia, and the IPV vaccine fulfills the Polio Eradication & Endgame Strategic Plan 2013-2018.
“Pneumonia is one of the leading causes of child mortality in Bangladesh, accounting for 22 percent of deaths of children under the age of 5, so the introduction of pneumococcal vaccine will have a major positive impact on child survival,” Gavi Vaccine Alliance CEO Seth Berkley said.
The introduction of these two novel vaccines into Bangladesh’s vaccine schedule is due to the support of WHO, UNICEF, Gavi, and the Global Polio Eradication Initiative partners.
“With high immunization coverage in Bangladesh, this introduction of two more vaccines, PCV and IPV, is a step in the right direction,” WHO's representative to Bangladesh N. Paranietharan said. “The inclusion of IPV in routine immunization in Bangladesh would help maintain Bangladesh’s polio-free status, and the introduction of cost-effective PCV would bring significant reduction in childhood diseases and deaths.”
UNICEF's Bangladeshi representative believes the introduction of PCV and IPV in the national immunization schedule will have a major impact on the reduction of under-5 mortality.
“Given the commitment and determination shown by the government and partners, UNICEF is confident that this momentous effort will make a significant and sustained contribution to child survival in Bangladesh through ensuring equitable access to all children,” Edouard Begibeder said.